InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,880.00
(
0.44%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.49
(
-0.12%
)
Bitcoin
62,642.27
(
3.06%
)
Post# of 252595
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 223292

Wednesday, 10/30/2019 12:33:48 PM

Wednesday, October 30, 2019 12:33:48 PM

Post# of 252595
COCP PR on 6w HCV regimen:

https://www.globenewswire.com/news-release/2019/10/30/1937841/0/en/Cocrystal-Pharma-Announces-New-Data-on-CC-31244-and-Abstract-Acceptance-for-Poster-Presentation-at-the-AASLD-2019-Liver-Meeting.html

Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR), which is considered a cure, using only 6 weeks of Epclusa’s therapy combined with only 2 weeks of CC-31244

As though a 67% SVR rate were something to boast about.

See #msg-146258764 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up